Skip to content

Tag: 5 alpha reductase inhibitors

Explore our medication guides and pharmacology articles within this category.

Can finasteride cause neurological problems? A comprehensive review

5 min read
Analyses of adverse event databases and patient reports have suggested a potential association between finasteride and neurological side effects, including mood and cognitive issues. The central question of whether **can finasteride cause neurological problems?** is a growing concern for patients considering this medication.

Understanding Which Tablet is used for urine flow: A Guide to Medications

4 min read
According to the Urology Care Foundation, millions of men experience bothersome urinary symptoms, often caused by benign prostatic hyperplasia (BPH). Finding out **which tablet is used for urine flow** is a critical step, but depends on the underlying cause, which can range from an enlarged prostate to an overactive bladder.

How hard is finasteride on the liver? An in-depth pharmacological review

5 min read
While finasteride is extensively metabolized by the liver, studies suggest that it is a very unlikely cause of clinically apparent liver injury. This comprehensive article reviews the available data to determine **how hard is finasteride on the liver**, detailing potential risks and necessary monitoring for individuals.

Understanding the Link: Can Finasteride Cause Moobs?

3 min read
While finasteride is prescribed to an estimated 200,000 patients for hair loss annually, a key concern for many is the question: **can finasteride cause moobs?** The answer is yes, though the risk is considered low, it is a recognized potential side effect.

Does finasteride cause gynecomastia? Understanding the Risk

4 min read
Drugs are a contributing factor in approximately 10-25% of all gynecomastia cases in men [1.2.3]. While uncommon, the question of 'Does finasteride cause gynecomastia?' is a valid concern for users of this popular hair loss medication, stemming from its hormonal mechanism of action [1.3.2, 1.3.4].